Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nintedanib + mFOLFOX6
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Nintedanib + mFOLFOX6 is a combination therapy consisting of **nintedanib**, a small molecule triple angiokinase inhibitor, and the **mFOLFOX6 chemotherapy regimen**, which includes oxaliplatin, folinic acid (leucovorin), and fluorouracil (5-FU)[1][3][5]. Nintedanib targets angiogenesis by inhibiting vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-3), and platelet-derived growth factor receptors (PDGFR α and β), thereby interfering with tumor blood vessel formation[3][5]. mFOLFOX6 is a widely used chemotherapy regimen that combines oxaliplatin, folinic acid, and fluorouracil for the treatment of colorectal cancer[2][4]. The combination has been investigated primarily for metastatic colorectal cancer (mCRC).
- Brand names
- Vargatef
- Other names
- nintedanib plus mFOLFOX6nintedanib + modified FOLFOX6
02
Targets
TS (Thymidylate synthase)LYN (LYN proto-oncogene, Src family tyrosine kinase)LCK (Proto-oncogene tyrosine-protein kinase Lck)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)FGFR2 (Keratinocyte growth factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)DNAVEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on nintedanib + mFOLFOX6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nintedanib + mFOLFOX6.